The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | MRD by next-generation sequencing versus next-generation flow: a comparison within the IsKia trial
Mattia D’Agostino, MD, University of Turin, Turin, Italy, shares insights from a prospective comparison within the Phase III IsKia trial (NCT04483739) of measurable residual disease (MRD) by next-generation sequencing versus next-generation flow. Dr D’Agostino highlights high concordance between the two techniques, indicating that both are effective in detecting MRD negativity. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So minimal residual disease is becoming more and more important in the myeloma field as a prognostic factor, as an accelerated approval endpoint in clinical trials and also to personalize treatment. There are two techniques that are standard of care and they are suggested by the IMWG to define MRD negativity in the bone marrow: next-generation sequencing and next-generation flow. We take advantage of the ISKIA trial where very high rates of MRD negativity have been achieved to look prospectively at a comparison of these two techniques in defining MRD negativity...
So minimal residual disease is becoming more and more important in the myeloma field as a prognostic factor, as an accelerated approval endpoint in clinical trials and also to personalize treatment. There are two techniques that are standard of care and they are suggested by the IMWG to define MRD negativity in the bone marrow: next-generation sequencing and next-generation flow. We take advantage of the ISKIA trial where very high rates of MRD negativity have been achieved to look prospectively at a comparison of these two techniques in defining MRD negativity. And what we found is that the concordance of the two techniques searching for MRD in the same sample was very good, was indeed above 88%. This was true both at 10 to minus 5 and at 10 to minus 6. So both techniques are indeed very good in detecting MRD negativity.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
M.D. has received honoraria from GlaxoSmithKline, Sanofi, and Janssen; and has served on the advisory boards for GlaxoSmithKline, Sanofi, and Bristol Myers Squibb.
